$LBRX (LB PHARMACEUTICALS) — 8-K: LB Pharmaceuticals appoints Joseph Miller as CFO ahead of NOVA-2 readout

LB Pharmaceuticals named Joseph Miller as Chief Financial Officer, citing his more than two decades of biopharmaceutical finance experience. He previously served as CFO of Aurinia Pharmaceuticals through the commercial launch of LUPKYNIS and as CFO of Avalo Therapeutics. The appointment comes as the company approaches pivotal NOVA-2 clinical trial results and prepares for the potential launch of LB-102 in schizophrenia.

LB Pharmaceuticals named Joseph Miller as Chief Financial Officer, citing his more than two decades of biopharmaceutical finance experience. He previously served as CFO of Aurinia Pharmaceuticals through the commercial launch of LUPKYNIS and as CFO of Avalo Therapeutics. The appointment comes as the company approaches pivotal NOVA-2 clinical trial results and prepares for the potential launch of LB-102 in schizophrenia.